Unexplained weight loss (UWL), defined as a loss of more than 5% of the total body weight within a span of six months, is a common yet perplexing clinical scenario. It is often a harbinger of serious underlying pathology, necessitating a thorough evaluation. This article aims to provide a comprehensive approach to the evaluation of UWL in clinical practice.
The initial evaluation should focus on a detailed history and physical examination. It is important to ascertain the time frame, amount of weight loss, and associated symptoms. A meticulous review of systems can often hint at the underlying cause. The role of medications, diet, and lifestyle changes should be explored. Physical examination should be comprehensive, focusing on signs of systemic diseases.
Basic laboratory studies should be done, including complete blood count, metabolic panel, liver function tests, thyroid function tests, and tumor markers. Imaging studies, such as CT scans or ultrasound, should be considered based on the clinical suspicion. Endoscopic procedures might be necessary in cases with gastrointestinal symptoms.
If the initial workup is unrevealing, specialized evaluations might be warranted. These could include psychiatric evaluation for eating disorders or depression, rheumatologic workup for connective tissue diseases, or oncologic evaluation for suspected malignancies. The choice of further investigations should be guided by the clinical picture.
Patients with UWL should be closely monitored. If no cause is found despite a thorough evaluation, careful follow-up is essential as some conditions might manifest later. Any new symptoms or signs should prompt a re-evaluation.
Evaluating UWL is a complex task requiring a systematic approach. A meticulous history, physical examination, and judicious use of investigations can often lead to the diagnosis. Close follow-up is crucial in cases where the cause remains elusive. By adopting a comprehensive approach, clinicians can ensure optimal care for patients experiencing UWL.
1.
Trial Supports Ivonescimab and Chemo for NSCLC Survival
2.
Cancer "Tidal Wave" Prediction: Not Cigarette-Based, Either! Wary Stories Regarding Cannabis and Cancer.
3.
Lymph node transfer reduces arm swelling after breast cancer surgery, study shows
4.
Silibinin is a novel and ancient molecule that highlights the significance of integrated therapies for cancer.
5.
Research Indicates that First-Line Immunotherapy Is Enough for Elderly NSCLC Patients?
1.
Unlocking the Power of Hematocrit: Exploring the Benefits of Blood Cell Counts
2.
Unpacking Chordoma: Understanding the Rare Cancer and its Treatment Options
3.
Colorectal Cancer Incidence Trends: A Growing Concern in 2024 and 2025
4.
Uncovering the Mysteries of the RDW Blood Test
5.
The Basics of Langerhans Cell Histiocytosis: Understanding a Rare Disease
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Navigating the Complexities of Ph Negative ALL - Part II
2.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management
3.
Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment
4.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
5.
Navigating the Complexities of Ph Negative ALL - Part XIV
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation